Azopt
indicated to manage glaucoma to alleviate ocular hypertension.
Strengths: 1%
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Carbonic Anhydrase Inhibitor
- Pharmacological class
Sulfonamide
- Contraindications
hypersensitivity to sulfonamides; severe renal impairment
- Minor side effects
bitter taste; blurred vision
- Moderate side effects
eye irritation; ocular pain
- Dosage forms
Eye drops, suspension
- Administration route
Ocular use
- Patient summary
indicated to manage glaucoma to alleviate ocular hypertension.
- Prescription status
POM
- Manufacturer
Novartis
- Onset Time
1–2 hours
- Duration
8–12 hours
- Storage instructions
Store below 30°C. Keep upright.
- Drug interactions
oral carbonic anhydrase inhibitors
- Pregnancy and breastfeeding
Pregnancy/breastfeeding: use only if the benefit justifies the potential risk.
Precautions and warnings
remove contact lenses before application; may impair driving ability; monitor for systemic effects
Serious side effects
anaphylaxis — requires immediate medical attention; stevens-johnson syndrome — requires immediate medical attention
Mechanism of action
Inhibits carbonic anhydrase in the eye, which reduces the production of aqueous humour, thereby lowering intraocular pressure.
Azopt
indicated to manage glaucoma to alleviate ocular hypertension.
Editorial Notes
- Active ingredient(s): Brinzolamide
- Listed indication(s): Glaucoma, Ocular Hypertension
Available option
- 2 bottles - 1 %1499-1-pct-17889